DeuterOncology NV was founded in September 2020 by Dr Timothy Perera and is based in Liege in Belgium.
The company generated pre-clinical validation of DO-2, a novel, highly selective, brain penetrant deuterated MET kinase and RAS pathway inhibitor. Timothy Perera was the originator of the initial idea for the use of deuteration as a means to modulate metabolic properties of the parent drug and remains a strong champion of this exciting new molecule.
The molecule was in-licensed (worldwide rights outside of greater China) from OCTIMET Oncology NV and originally licensed from Janssen Pharmaceutica in 2017.
DeuterOncology has initiated a phase 1 clinical study to validate DO-2 as a ‘Best in Class’ MET kinase inhibitor as suggested by the strong preclinical data package. DeuterOncology works together with a broad established network of collaborators across the world to achieve its mission to bring new solutions to cancer patients.